ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk.

Front Immunol · 2022 · PMC9294453 · PMID 35865520

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference between findings of the groups did not reach statistical significance, it is worth mentioning that antibodies against SARS-CoV-2 were detected in only 1.3% (2 of 153) placebo recipients, compared to 4.7% (7 of 148) BCG recipients (p = 0.099).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.